Cardiovascular Implications of Immune Disorders in Women.
Caitlin A Moran, Lauren F Collins, Nour Beydoun...
https://pubmed.ncbi.nlm.nih.gov/35175848/Actively Recruiting
Led by University of California, San Diego · Updated on 2026-07-13
100
Participants Needed
1
Research Sites
13 weeks
Total Duration
This research aims to evaluate the effect of adding inclisiran to the standard care for lowering LDL cholesterol in patients at high cardiovascular risk who have multiple health conditions and take five or more medications that interact with statins. These patients often have autoimmune diseases, liver disease, chronic kidney disease, diabetes, or have had organ transplants, and face challenges in optimizing statin therapy due to drug interactions. The study is a randomized, open-label trial focusing on improving LDL levels in this vulnerable group. Participants will be randomly assigned to one of two groups one receiving subcutaneous inclisiran injections plus their usual care, and the other continuing with their standard lipid-lowering therapy alone. Patients in the inclisiran group will receive three doses of 284 mg at baseline, 3 months, and 9 months. The control group will maintain their current therapy without changes. The study includes five visits over 12 months screening, baseline, 3 months, 9 months, and 12 months. During each visit, participants will have blood tests to measure LDL cholesterol and other markers, medical history and medication reviews, and complete surveys. The primary outcome is the change in LDL cholesterol after 12 months. The study tracks adherence to the treatment plan and lifestyle guidance. Safety and treatment effects will be monitored throughout the year-long study period.
CONDITIONS
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
P
Pam Taub, MD
A
Antoinette S Birs, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Diego
Lead Sponsor
Novartis
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Inclisiran Injection (284mg, SC, at baseline, 3 & 9 months) | Maximal Tolerated Statin or No Statin (Intolerance), No Additional Intervention |
|---|---|---|
| What is it? | Subcutaneous injection of inclisiran, a small interfering RNA therapy targeting PCSK9 to reduce LDL-cholesterol. Given at baseline, 3 months, and 9 months. | Standard care with maximal tolerated statin therapy, or no statin if intolerance, with no additional intervention. Patients continue their existing regimen. |
| Role in the trial | Investigational arm; patients receive inclisiran injection in addition to their baseline regimen. | Control arm; patients remain on maximal tolerated statin or no statin, and do not receive additional pharmacologic intervention. |
| Primary use or purpose | Lower LDL-cholesterol in adults where drug-drug interactions or statin intolerance limit conventional LDL lowering. Aims to reduce cardiometabolic risk with durable dosing. | Maintain LDL-cholesterol levels on maximal tolerated statin or no statin if intolerance. No new intervention applied; reflects current baseline care limitations. |
| How is it given/performed? | Inclisiran is administered as a subcutaneous injection at baseline, month 3, and month 9. No additional drug adjustments required. | Participants continue their regular statin therapy or none if statin intolerance, without change or extra procedure. |
| Evidence status | Multiple phase 3 trials show inclisiran reduces LDL-cholesterol by ~50% with twice-yearly dosing in high-risk populations, including those with statin intolerance. | Statins are proven to lower LDL, but in this population drug-drug interactions and intolerance can severely limit LDL reduction. Many patients cannot achieve guideline targets. |
| Important limitations | Long-term safety data for inclisiran in patients with multiple comorbidities and medications remains limited. Effects on cardiovascular outcomes require further evidence beyond LDL reduction. | Drug-drug interactions and statin intolerance prevent many patients from achieving guideline LDL targets. No alternative is provided in this arm. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive either subcutaneous inclisiran injections plus standard care or continue standard care alone.
5 visits including screening, baseline, 3 months, 9 months, and 12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Caitlin A Moran, Lauren F Collins, Nour Beydoun...
https://pubmed.ncbi.nlm.nih.gov/35175848/C M Otto, B K Lind, D W Kitzman...
https://pubmed.ncbi.nlm.nih.gov/10403851/Kausik K Ray, R Scott Wright, David Kallend...
https://pubmed.ncbi.nlm.nih.gov/32187462/Matthew J Budoff, April Kinninger, Heidi Gransar...
https://pubmed.ncbi.nlm.nih.gov/37227328/Caroline S Fox, Ramachandran S Vasan, Helen Parise...
https://pubmed.ncbi.nlm.nih.gov/12654605/Frederick J Raal, David Kallend, Kausik K Ray...
https://pubmed.ncbi.nlm.nih.gov/32197277/Carlos Iribarren, Malini Chandra, Catherine Lee...
https://pubmed.ncbi.nlm.nih.gov/35290077/Barbara S Wiggins, Joseph J Saseen, Robert L Page...
https://pubmed.ncbi.nlm.nih.gov/27754879/John E Hughes, Catherine Waldron, Kathleen E Bennett...
https://pubmed.ncbi.nlm.nih.gov/36692678/R Scott Wright, Kausik K Ray, Frederick J Raal...
https://pubmed.ncbi.nlm.nih.gov/33663735/University of California, San Diego
Lead Sponsor
Novartis
Collaborating Sponsor